Talazoparib-impurities | Pharmaffiliates

Talazoparib

Talazoparib, sold under the brand name Talzenna, is an orally available poly ADP ribose polymerase inhibitor developed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations. Reference standards of Talazoparib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.

stdClass Object
(
    [pname] => Talazoparib - API Standards
    [catalogue_number] => PA 20 3890000
    [category_ids] => ,76,78,70,82,
    [chemical_name] => 
    [weight] => 380.36
    [form] => C19H14F2N6O
    [cas] => 1207456-01-6
    [pslug] => 1207456-01-6-talazoparib-api-standards-pa203890000
    [latest_product] => 0
    [linkproducts] => 0
    [offers_id] => 
    [offers_name] => 
    [offers_status] => 
    [offers_start_date] => 
    [offers_end_date] => 
    [pageview] => 
    [offers_slug] => 
    [offers_product_id] => 
    [offers_product_code] => 
    [offers_master_id] => 
    [offer_percentage] => 
    [offers_product_main_cat] => 
)
PA 20 3890000

Talazoparib - API Standards


  • Catalogue No.:PA 20 3890000

  • CAS :

    1207456-01-6

  • Molecular Formula : C19H14F2N6O

  • Molecular Weight : 380.36